Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07039669
PHASE3

Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

View on ClinicalTrials.gov

Summary

The objective of the study was to evaluate the efficacy and safety of 611 in Chinese adults with moderate to severe COPD.

Official title: A Multi-Centered, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial, to Evaluate the Efficacy and Safety of 611 in Chinese Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease

Key Details

Gender

All

Age Range

40 Years - 85 Years

Study Type

INTERVENTIONAL

Enrollment

594

Start Date

2025-07-16

Completion Date

2028-11

Last Updated

2025-11-18

Healthy Volunteers

No

Interventions

DRUG

611

611 subcutaneous (SC) injection

DRUG

Placebo

placebo Q2W, subcutaneous (SC) injection

Locations (4)

China-Japan Friendship Hospital

Beijing, Beijing Municipality, China

Shenzhen People's Hospital

Shenzhen, Guangdong, China

Jiangsu Province Hospital

Nanjing, Jiangsu, China

ZheJiang Provincial People's Hospital

Hangzhou, Zhejiang, China